Navigation Links
Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid

orie, high-fat breakfast and took the study drug 30 minutes later. Blood samples for morphine pharmacokinetic analysis were drawn prior to dosing and at intervals from 0.5 to 168.0 hours post-dose.

The results of the pharmacokinetic analysis demonstrated, for both the fasted and fed states that the release characteristics of morphine were consistent with a sustained-release formulation and were similar to previous study results for KADIAN(R) (morphine sulfate extended-release) Capsules. Most naltrexone levels were below the assay measurement limits. Adverse events, reported in five subjects, were mild to moderate in intensity and resolved without treatment.

This study was conducted as part of Alpharma's medical development program for its abuse-deterrent morphine product, and its results were consistent with data generated in the Phase II clinical program for this product.. The company is targeting an NDA filing for its abuse-deterrent product in the first half of 2008.

Other Data Presented on KADIAN(R) Capsules

Also presented at the annual meeting were data that showed the extended- release properties of KADIAN(R) were maintained even in the presence of a significant quantity of alcohol. These results indicate that the concomitant use of tested levels of alcohol with KADIAN(R) has no significant impact on mean morphine blood levels or the timing of morphine release. Recently, the U.S. Food and Drug Administration completed a review of this data and concluded that the KADIAN(R) black box warning did not need to include any precautionary language related to alcohol.

About KADIAN(R) Capsules

KADIAN(R) capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate-to-severe pain, when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. The capsules can be taken once-daily (q24h) or twice-daily (q12h), as prescribed, to provide up to 24 hours o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... a corporate update and report second quarter 2014 financial ... Friday, August 1, 2014. That same day, Arena will ... Eastern Time (5:30 a.m. Pacific Time). ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/24/2014)... 2014  Parnell Pharmaceuticals Holdings Ltd announces the ... added to Parnell,s already extensive pipeline through a ... biotechnology company. The compounds now known as PAR ... bone regeneration and dermal regeneration, respectively. Parnell has ... the veterinary market with the potential to also ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4
... VIENNA, Va., Nov. 3 CEL-SCI Corporation,(NYSE: ... expanded its exclusive licensing,agreement for Multikine(R) with Orient ... from Taiwan. The new,agreement extends the Multikine collaboration ... New Zealand. The licensing agreement,initially focuses on the ...
... - Data presented at the 2008 iSBTc Annual Meeting ... at 11:00 a.m. ET to discuss,results -, BRANFORD, ... announced today preliminary data from an ongoing Phase II,trial ... treatment of patients with unresectable Stage III or Stage ...
Cached Medicine Technology:CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:7/25/2014)... 25, 2014 (HealthDay --, Treatment for lymphoma may lower ... and non-Hodgkin lymphoma, which are cancers of the body,s ... still in their reproductive years. For men, treatment for ... most men regain their fertility within two years of ... about the possibility of this significant side effect before ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... The new report “Carbohydrase Market ... and Others), by Type (Amylases, Cellulases, and Others), ... Global Trends & Forecasts to 2019", by MarketsandMarkets, ... global Carbohydrase market with analysis of trends, opportunities, ... and values are forecasted on the basis of ...
(Date:7/25/2014)... Richardson, Texas (PRWEB) July 25, 2014 ... years of operations at their office location by expanding ... first of a kind comprehensive visual electro-physiology clinic. , ... and with years of experience in vision problems, patients ... studies can now take advantage of the implementation of ...
(Date:7/25/2014)... European liquid chromatography reagents report defines and segments the ... revenue. The liquid chromatography reagents market in Europe was ... estimated to grow to around $1581.8 million by 2018, ... 2018. , Browse through the TOC of the European ... the in-depth analysis provided. This also provides a glimpse ...
Breaking Medicine News(10 mins):Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4
... According to a study of patients, doctors and family ... When someone has a terminal illness, they may have ... 'living will'. For example they may not wish to ... realistic chance of recovery. But other people, even though ...
... better than conventional treatment for managing asthma attacks. ... immune cells known eosinophils increase// in the airways. ... how targeting this build up of eosinophils in ... asthma attack. ,The conventional treatment consists ...
... is observed that statins reduce the risk of heart attack ... and so lowers the risk of heart disease. This has ... the benefits for the elderly have not been so clear. ... the benefit of treatment with the statin drug pravastatin in ...
... new study observed that people reporting symptoms of anxiety were ... It was long believed that worry gave you ulcers.// ... pylori was a major risk factor, and the link with ... now report that people with generalized anxiety do seem to ...
... with animals say they have located the genes related ... they say it could one day lead to better ... research into this area was only able to locate ... of how the genes work together during memory formation. ...
... researchers observe that stress hormones may be disregulated in ... a hormonal system that helps the body deal with ... production of the stress hormone cortisol by the adrenal ... pains and overwhelming tiredness. It's cause is not well ...
Cached Medicine News:
... Portable - Battery Powered (6 size AA ... conversion (g, ct, oz, ozt, GN, dwt, ... Counting and Percent Measure functions, Auto Print. ... Optional AC adapter may be ordered for ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Medicine Products: